Tag archive for ‘Merck’
Divi's Laboratories to manufacture API of MSD’s Covid drug Molnupiravir
By businessnewstoday On Thursday, May 27th, 2021
0 Comments

Divi’s Laboratories to manufacture API of MSD’s Covid drug Molnupiravir

Divi’s Laboratories Limited has been selected by pharma giant MSD (known as Merck in the US and Canada) as an authorized manufacturer for the active pharmaceutical ingredient (API) of the latter Covid-19 drug More...

Dr. Reddy's Laboratories launches Ertapenem for Injection in US
By businessnewstoday On Wednesday, May 12th, 2021
0 Comments

Dr. Reddy’s Laboratories launches Ertapenem for Injection in US

Dr. Reddy’s Laboratories has launched Ertapenem for Injection, 1 g/vial, a generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial, which has approval from the US Food and Drug Administration More...

Cipla partners with MSD to manufacture and distribute Molnupiravir drug to treat Covid-19
By businessnewstoday On Wednesday, April 28th, 2021
0 Comments

Cipla partners with MSD to manufacture and distribute Molnupiravir drug to treat Covid-19

Cipla has entered into a non-exclusive licensing agreement with MSD (called Merck in the US and Canada) for the manufacturing and distribution of Molnupiravir (EIDD-2801/MK-4482), an investigational oral antiviral More...

Merck wraps up $1.8bn acquisition of Pandion Therapeutics
By businessnewstoday On Sunday, April 11th, 2021
0 Comments

Merck wraps up $1.8bn acquisition of Pandion Therapeutics

Merck has wrapped up its previously announced $1.85 billion acquisition of Massachusetts-based clinical-stage biotech company Pandion Therapeutics. The pharma giant said that it had successfully completed the cash More...

Merck acquisition of Pandion Therapeutics
By businessnewstoday On Thursday, February 25th, 2021
0 Comments

Merck to acquire US biotech company Pandion Therapeutics for $1.8bn

Merck has agreed to acquire Pandion Therapeutics, a Massachusetts-based clinical-stage biotech company, for about $1.85 billion in an all-cash deal. Pandion Therapeutics is engaged in developing therapeutics for More...

Day One Biopharmaceuticals, Merck sign licensing deal for MEK Inhibitors
By businessnewstoday On Tuesday, February 23rd, 2021
0 Comments

Day One Biopharmaceuticals, Merck sign licensing deal for MEK Inhibitors

Day One Biopharmaceuticals has signed a licensing agreement with Merck to develop and commercialize pimasertib and MSC2015103B, two oral, small molecule allosteric inhibitors of MEK 1/2. MEK 1/2 is a key enzyme More...

By pharmanewsdaily On Tuesday, November 24th, 2020
0 Comments

Merck seeks FDA and EMA approvals for V114 pneumococcal conjugate vaccine candidate

V114 pneumococcal conjugate vaccine candidate : Merck has submitted applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval for V114, its 15-valent pneumococcal More...

By pharmanewsdaily On Tuesday, November 24th, 2020
0 Comments

Merck to acquire OncoImmune for Covid-19 drug candidate CD24Fc

Merck acquisition of OncoImmune : Pharma giant Merck has signed an all-cash deal worth $425 million to acquire OncoImmune to gain access to the latter’s investigational Covid-19 drug – CD24Fc. Based in Maryland, More...

MSCP wraps up $330m sale of majority stake in Hojeij Branded Foods to Lagardere
By pharmanewsdaily On Sunday, November 8th, 2020
0 Comments

Merck to acquire US biopharma company VelosBio to strengthen oncology pipeline

Merck acquisition of VelosBio : US pharma giant Merck has agreed to acquire VelosBio, a California-based clinical-stage biopharma company, for $2.75 billion in an all-cash deal, in a move to strengthen its oncology More...

By pharmanewsdaily On Monday, September 14th, 2020
0 Comments

Seattle Genetics signs $4.4bn worth oncology deals with Merck

US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major pharma companies will develop and commercialize Seattle More...